Training in Adults With Parkinson's Disease

November 3, 2026 updated by: Rodrigo Santiago Barbosa Rocha, Universidade do Estado do Pará

Training on Respiratory Parameters in Older Adults With Parkinson's Disease

Patients with Parkinson's disease experience progressive deconditioning of the respiratory muscles, leading to weakness and potential ventilatory impairments. Evidence indicates that physical exercise positively affects these muscles in people with various clinical conditions. This study will evaluate the effects of multicomponent and resistance training on respiratory parameters and physical and functional capacities in individuals with Parkinson's disease. A total of 40 patients will be randomly allocated to two groups: 20 individuals in the multicomponent training group and 20 in the resistance training group. Both groups will undergo a three-month intervention with two sessions per week. All participants must continue standard pharmacological treatment for Parkinson's disease. Respiratory parameters will be assessed using respiratory pressure measurement and spirometry. Physical and functional capacities will be assessed using the Rikli and Jones test battery.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Hoehn and Yahr stages 1-3
  • Physical and mental requirements,
  • No history of exercise training in the preceding three months.
  • Standard pharmacological treatment for PD throughout the 12-week study period.

Exclusion Criteria:

  • Mini-Mental State Examination score <24
  • Unstable cardiovascular disease or any other uncontrolled chronic condition

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Aerobic training

The first group will undergo multicomponent training for three months, with two sessions per week

Resistence training

Active Comparator: Resistance training

The second group will undergo resistance training for the same period

Resistence training

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Inspiratory pressure
Time Frame: three weeks

Respiratory muscle strength will be assessed using a manovacuometer with a range of -300 to +300 cmH2O. Respiratory muscle strength during inspiration will be assessed.

three weeks
Forced Vital Capacity
Time Frame: three weeks

Forced vital capacity, expressed in liters, will be assessed based on the maximum volume of inspired air, which will be measured in liters using a spirometer

three weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 15, 2026

Primary Completion (Estimated)

December 20, 2027

Study Completion (Estimated)

January 15, 2028

Study Registration Dates

First Submitted

October 27, 2026

First Submitted That Met QC Criteria

November 3, 2026

First Posted (Actual)

November 10, 2026

Study Record Updates

Last Update Posted (Actual)

November 10, 2026

Last Update Submitted That Met QC Criteria

November 3, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 430-12412-34-340234-04234-1321

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.